{"id":927287,"date":"2026-01-14T08:59:06","date_gmt":"2026-01-14T13:59:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/"},"modified":"2026-01-14T08:59:06","modified_gmt":"2026-01-14T13:59:06","slug":"class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/","title":{"rendered":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026"},"content":{"rendered":"
\n

PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC<\/u><\/a> announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE)<\/strong> (\u201cSkye\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025 <\/strong>(the \u201cClass Period\u201d), inclusive.<\/p>\n

\n
\n Investor Deadline:<\/em>
\n <\/strong>
\n Investors who purchased Skye<\/em>
\n securities during the Class Period may, no later than <\/em>
\n
\n January 16, 2026<\/em>
\n <\/strong>
\n , seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/em>
\n
\n
\n CLICK HERE<\/u>
\n <\/strong>
\n <\/a>.<\/p>\n

Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.<\/p>\n

The complaint asserts that, throughout the Class Period, Defendants failed to disclose that: (i) the efficacy of nimacimab, Skye\u2019s lead product candidate, was lower than what had been represented to investors; and (ii) as a result, the drug\u2019s clinical and commercial potential had been overstated.<\/p>\n

On October 6, 2025, Skye issued a press release announcing topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, disclosing that that the primary endpoint of 8% difference in weight loss compared to placebo had not been met. Following these disclosures, Skye\u2019s stock price declined $2.85 per share, or 60%<\/strong>, closing at $1.90 on October 6, 2025.<\/p>\n

\n
\n If you are a Skye investor and would like to learn more about this action, <\/em>
\n <\/strong>
\n
\n
\n
\n CLICK HERE<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or please contact Berger Montague: Andrew Abramowitz at <\/em>
\n <\/strong>
\n
\n
\n
\n aabramowitz@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (215) 875-3015, or Caitlin Adorni at <\/em>
\n <\/strong>
\n
\n
\n
\n cadorni@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (267)764-4865.<\/em>
\n <\/strong>\n <\/p>\n

\n About Berger Montague<\/strong>
\n
Berger Montague is one of the nation\u2019s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n

\n For more information or to discuss your rights, please contact:<\/strong>
\n
Andrew Abramowitz
Senior Counsel<\/em>
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com<\/p>\n

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services<\/em>
Berger Montague
(267) 764-4865
cadorni@bergermontague.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (\u201cSkye\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025 (the \u201cClass Period\u201d), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class … <\/p>\n

Continue reading “CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-927287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (\u201cSkye\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025 (the \u201cClass Period\u201d), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class … Continue reading "CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:59:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026\",\"datePublished\":\"2026-01-14T13:59:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/\",\"name\":\"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=\",\"datePublished\":\"2026-01-14T13:59:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/","og_locale":"en_US","og_type":"article","og_title":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk","og_description":"PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (\u201cSkye\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired Skye securities during the period of\u00a0November 4, 2024 through October 3, 2025 (the \u201cClass Period\u201d), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases. The complaint asserts that, throughout the Class … Continue reading \"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-14T13:59:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026","datePublished":"2026-01-14T13:59:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/"},"wordCount":424,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/","name":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=","datePublished":"2026-01-14T13:59:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTE2OCM3MzU5ODIwIzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-deadline-approaching-berger-montague-advises-skye-bioscience-inc-nasdaq-skye-investors-to-inquire-about-a-securities-fraud-class-action-by-january-16-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=927287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=927287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=927287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=927287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}